证券代码：600201 证券简称：生物股份 公告编号：临 2026-005 金宇生物技术股份有限公司 关于子公司取得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据国家《兽药管理条例》和《兽药注册办法》规定，经国家农业农村部审 查，批准金宇生物技术股份有限公司（以下简称"公司"）全资子公司金宇优邦 生物科技（江苏）有限公司（以下简称"金宇优邦"）与其他单位联合研制的鹅新 城疫、小鹅瘟二联灭活疫苗（A-VII 株+GPVP3/Bac 株）为新兽药，详情如下： 用法与用量：胸部肌肉注射。种鹅开产前 5 周注射 1.0ml，3 周后以相同剂量 加强免疫一次。 贮藏与有效期：2～8℃保存，有效期为 12 个月。 二、新兽药产品研发情况 新城疫、小鹅瘟病毒，是危害水禽业的两大重要疫病，给养禽业造成了巨大 损失。公司与其他单位联合开发的鹅新城疫、小鹅瘟二联灭活疫苗（A-VII 株 +GPVP3/Bac 株），采用胚毒生产工艺及杆状病毒表达工艺，应用昆虫表达系统 可高效表达蛋白，具有免疫原性好、抗体产生快、可大规模 ...

量化金融研究丨深度报告 [Table_Title] 农牧渔 ETF 景顺（560210）：生猪产能去化+种 业振兴，布局农业变革核心赛道 %% %% %% %% research.95579.com 报告要点 [Table_Summary] 农牧渔指数行业分布呈现"核心聚焦、多元协同"的格局，重点倾斜生猪、种子两大热门细分 方向，具体分布如下：截至 2026 年 3 月 17 日，整体以养殖业为核心，占比高达 47.41%，单 只样本股权重上限为 15%，前两大权重股权重高度集中，规模化集中、行业向头部聚集的发展 趋势，凸显生猪赛道的核心价值与投资潜力；种植业占比 15.52%，重点覆盖种子这一热门细 分方向，贴合国家种业振兴政策导向，受益于生物育种产业化推进的行业红利，彰显种子作为 农业"芯片"的核心地位。 分析师及联系人 [Table_Author] 秦瑶 刘胜利 SAC：S0490513080002 SAC：S0490517070006 SFC：BWH883 请阅读最后评级说明和重要声明 2 / 21 %% %% %% %% research.95579.com 1 丨证券研究报告丨 2 [Table_ ...

格隆汇3月8日丨四环医药(00460.HK)公告，根据上海证券交易所及深圳证券交易所于2026年3月6日分别 发布的《关于沪港通下港股通标的调整的通知》、《关于深港通下的港股通标的证券名单调整的公 告》，集团旗下非全资附属公司轩竹生物科技股份有限公司("轩竹生物")被调入沪港通与深港通下港股 通标的名单，自2026年3月9日起正式生效。 沪港通及深港通是香港与中国内地的资本市场投资者间的股票交易与投资的渠道。董事会认为，轩竹生 物被调入沪港通与深港通下港股通标的名单，将有助于扩大轩竹生物的股东群体并提升其股份的交易流 动性。集团亦将直接受益于轩竹生物价值的重估与市场表现的提升，有助于进一步释放集团于创新药领 域的内在价值。 ...

Investment Rating - The industry investment rating is "Leading the Market - A" [6] Core Viewpoints - The report indicates that the pork price is expected to fluctuate weakly in the short term due to weak post-holiday consumption and sufficient supply [21][22] - The poultry market is experiencing fluctuations, with an increase in slaughter capacity post-holiday, while the white feather broiler market is in a downward trend [36] - The aquaculture sector shows stable prices for various fish species, but a decline in shrimp prices [43] Summary by Sections 1. Weekly Market Review - The agricultural sector increased by 4.01% during the latest trading week, outperforming the Shanghai and Shenzhen indices [14] - The fishery sector saw a slight decline, while other sub-sectors such as planting, feed, and livestock showed increases [17] 2. Industry Data Tracking 2.1. Swine Farming - The average price of live pigs is 10.93 CNY/kg, down 7.06% week-on-week and 5.73% over two weeks [20] - The average daily slaughter volume is 137,600 pigs, a decrease of 45.81% week-on-week [21] 2.2. Poultry Farming - The average price of white feather broilers is 7.47 CNY/kg, down 0.13% week-on-week [36] - The price of broiler chicks is 2.87 CNY/chick, up 2.40% week-on-week [36] 2.3. Planting Sector - The average price of corn is 2381.80 CNY/ton, up 0.46% week-on-week [39] - The average price of domestic wheat is 2532.59 CNY/ton, up 0.07% week-on-week [39] 2.4. Aquaculture Sector - The average price of carp is 20.00 CNY/kg, stable week-on-week, with a year-on-year increase of 11.11% [43] - The average price of shrimp is 300.00 CNY/kg, down 6.25% week-on-week [43]

Financial Performance Summary - In 2025, the company reported a total operating revenue of 139,028.74 million RMB, representing a year-on-year decrease of 17.06% [1] - The net profit attributable to the parent company was 13,761.67 million RMB, down 59.86% year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 4,599.98 million RMB, a decline of 85.79% year-on-year [1] - Basic earnings per share were 0.33 RMB, reflecting a decrease of 60.24% compared to the previous year [1] Asset and Equity Overview - As of the end of the reporting period, total assets amounted to 975,181.82 million RMB, a decrease of 2.98% from the beginning of the period [2] - The equity attributable to the parent company was 935,998.52 million RMB, down 2.12% from the beginning of the period, primarily due to dividend distribution and stock buybacks [2] Factors Affecting Performance - The decline in operating revenue was mainly influenced by changes in the domestic rabies vaccine market, including regulatory policy changes and intensified market competition, leading to reduced market demand [2] - Increased asset impairment losses were due to the company's strategic adjustment in R&D, specifically the termination of the hib vaccine project, resulting in full impairment of capitalized R&D investments [2] - The increase in fair value changes was attributed to the recovery in asset valuations within the innovative drug sector of the private equity investments [2] - The company experienced growth in overseas sales and managed to control selling and administrative expenses effectively, which helped mitigate some downward pressure on performance [2]

一、2025年度主要财务数据和指标 单位：元 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以公司2025年年 度的定期报告为准，提请投资者注意投资风险。 ■ 随着公司研发项目的快速推进及国际合作的开展，公司也获得了政府专项补助和国际专项研发资金的支 持，并于报告期确认了相关的非经常性收益。 （二）上表中有关项目增减变动幅度达30%以上的主要原因 报告期内，营业利润、利润总额及归属于母公司所有者的净利润均同比实现扭亏为盈；基本每股收益、 加权平均净资产收益率由负转正；归属于母公司所有者的扣除非经常性损益的净亏损同比收窄，上述变 动主要系：报告期内，公司营业总收入同比增长26.18%，公司持续优化资源配置、推行降本增效措 施，经营效率持续提升，报告期内多项费用实现节约，亦实现与政府专项补助和国际专项研发资金支持 相关的收益，因此，报告期多项盈利能力相关的主要财务数据和指标实现同比正增长。 注：1、本报告期初数同法定披露的上年年末数。 2、以上主 ...

Group 1 - The company received approval from the National Medical Products Administration to expand the age range for its ACYW135 meningococcal polysaccharide conjugate vaccine (CRM197 carrier) from "3 months to 3 years (47 months) children" to "3 months to 6 years (83 months) children" [1] - The product, branded as "Mankai Xin," is the first quadrivalent meningococcal conjugate vaccine approved in China, which was launched in December 2021, addressing the gap in high-end vaccines in the country and providing a better solution for preventing meningococcal disease in children under 6 years old [2] - The expansion of the age range for Mankai Xin is expected to positively impact the company's performance by facilitating further promotion and use of the vaccine, with the company committed to advancing production, batch release, and market sales [2]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 辽宁成大生物股份有限公司（以下简称"公司"）全资子公司成大生物（本溪）有限公司（以下简称"本 溪子公司"）于近日收到国家药品监督管理局签发的冻干人用狂犬病疫苗（人二倍体细胞）（以下简 称"人用二倍体狂犬疫苗"）《药品注册证书》。现将相关情况公告如下： 药品批准文号：国药准字S20260012 药品批准文号有效期：至2031年02月09日 上市许可持有人：成大生物（本溪）有限公司 生产企业：成大生物（本溪）有限公司 证书编号：2026S00502 一、药品基本情况 药品名称：冻干人用狂犬病疫苗（人二倍体细胞） 剂型：注射剂 规格：按标示量复溶后每瓶1.0ml。每1次人用剂量为1.0ml，狂犬病疫苗效价应不低于2.5IU。 批准事项：药品注册（境内生产） 注册分类：预防用生物制品 三、对公司的影响 辽宁成大生物股份有限公司 本次本溪子公司人用二倍体狂犬疫苗获批上市，将进一步完善公司疫苗产品布局，增强核心竞争力，巩 固在狂犬病疫苗领 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 康希诺生物股份公司 关于ACYW135群脑膜炎球菌多糖结合疫苗（CRM197载体）获得补充申请批准通知书的公告 证券代码：688185 证券简称：康希诺 公告编号：2026-003 康希诺生物股份公司 关于ACYW135群脑膜炎球菌多糖结合疫苗（CRM197 一、产品及补充申请情况 药品名称：ACYW135群脑膜炎球菌多糖结合疫苗（CRM197载体） 商品名称：曼海欣? 剂型：注射剂 载体）获得补充申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 近日，康希诺生物股份公司（以下简称"公司"）收到国家药品监督管理局下发的《药品补充申请批准通 知书》，公司产品ACYW135群脑膜炎球菌多糖结合疫苗（CRM197载体）（以下简称"MCV4"）适用人 群年龄范围由"3月龄~3周岁（47月龄）儿童"扩大至"3月龄~6周岁（83月龄）儿童"。现将相关情况公告 如下： 注册分类：预防用生物制品 准文号：国药准字S20210054 上市许可持有人：康希诺生物股份公司 主 ...

Core Viewpoint - The company has received a drug registration certificate for its lyophilized human rabies vaccine (human diploid cells), marking a significant advancement in its vaccine product portfolio and enhancing its market position in the rabies vaccine sector [1][5]. Group 1: Drug Information - The drug is a lyophilized human rabies vaccine (human diploid cells) with an injection form, where each bottle contains 1.0ml, and the efficacy must not be less than 2.5 IU per dose [1][2]. - The vaccine is classified as a preventive biological product, with the approval number valid until February 9, 2031 [2]. Group 2: Market Context - Rabies has a high mortality rate, with nearly 100% fatality once symptoms appear, resulting in approximately 60,000 deaths globally each year, posing a significant threat to public health [2]. - The vaccine utilizes human diploid cells (MRC-5) for cultivation, which is recognized for its excellent immunogenicity and safety, particularly suitable for individuals with weaker immune systems [3]. Group 3: Competitive Advantage - The vaccine is the first in China to include three immunization schedules: "simple 4-dose," "2-1-1," and "5-dose," providing flexibility for different exposure levels and patient compliance [3]. - This diverse immunization approach is expected to improve overall vaccination completion rates and optimize post-exposure prevention strategies, enhancing the company's competitive edge in the market [3]. Group 4: Company Impact - The approval of the human diploid rabies vaccine will enhance the company's vaccine product layout and strengthen its core competitiveness, injecting new growth momentum into its ongoing development [5].